Why the study?
Does the ACURATE neo transfemoral transcatheter heart valve provide safe and effective outcomes at 30 days in an unselected all-comers population with severe aortic stenosis?
Does the ACURATE neo transfemoral transcatheter heart valve provide safe and effective outcomes at 30 days in an unselected all-comers population with severe aortic stenosis?
The ACURATE neo prosthesis demonstrated good clinical outcomes with very low complication rates, including 1.4% 30-day mortality and 8.3% new pacemaker rate, in a real-world all-comers population with severe aortic stenosis.
Answers are grounded in this paper and cite their sources.
Low event rates support ACURATE neo feasibility in severe AS; leaves open randomized comparisons to current valves.
AIMS: The aim of the SAVI TF registry was to assess the safety and performance of the self-expanding ACURATE neo transfemoral transcatheter heart valve in a large patient population with severe aortic stenosis and to investigate whether the outcomes obtained in the CE-mark cohort can be replicated in an unselected all-comers population. METHODS AND RESULTS: From October 2014 until April 2016, 1,000 patients were enrolled in this prospective, European multicentre registry. Patients were 81.1±5.2 years and had a logistic EuroSCORE II and STS score of 6.6±7.5% and 6.0±5.6%, respectively. Predilatation was performed in 96.1% of patients and postdilatation in 44.8%. Procedural and device success were both obtained in 98.7%; failure comprised nine valve-in-valve procedures, three conversions to surgery, and one aborted procedure. The primary endpoint was 30-day mortality, which was observed in 14 patients (1.4% [95% CI: 0.7-2.1]). Disabling stroke was seen in 1.2% (95% CI: 0.5-1.9) and new pacemaker implantation in 8.3% (95% CI: 6.6-10.0). At discharge, mean effective orifice area was 1.77±0.46 cm² and mean gradient 8.4±4.0 mmHg; 4.1% of patients had a more than mild paravalvular leak. CONCLUSIONS: In this initial experience, treatment with the ACURATE neo prosthesis resulted in good clinical outcomes with very low complication rates.
No takes yet. Share an insight, caveat, or question.
Möllmann et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: